ADCT – Adc Therapeutics SA
ADCT — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
6.49
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.02
EPS Last/This Y
-0.03
EPS This/Next Y
0.08
Price
1.34
Target Price
2.62
Analyst Recom
2.2
Performance Q
21.83
Upside
-970.1%
Beta
1.8
Ticker: ADCT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-15 | ADCT | 1.485 | 0.00 | 1.00 | 3108 |
| 2026-10-16 | ADCT | 1.405 | 0.00 | 999.99 | 3109 |
| 2026-10-19 | ADCT | 1.46 | 0.00 | 0.00 | 2585 |
| 2026-10-20 | ADCT | 1.52 | 0.00 | 0.00 | 2789 |
| 2026-10-21 | ADCT | 1.51 | 0.00 | 0.00 | 2791 |
| 2026-10-22 | ADCT | 1.595 | 0.00 | 0.00 | 2791 |
| 2026-10-23 | ADCT | 1.44 | 0.00 | 0.00 | 2796 |
| 2026-10-26 | ADCT | 1.505 | 0.00 | 0.00 | 2818 |
| 2026-10-27 | ADCT | 1.598 | 0.00 | 0.00 | 2818 |
| 2026-10-28 | ADCT | 1.615 | 0.00 | 0.00 | 2818 |
| 2026-10-29 | ADCT | 1.495 | 0.00 | 0.00 | 2743 |
| 2026-10-30 | ADCT | 1.53 | 0.00 | 0.00 | 2743 |
| 2026-11-02 | ADCT | 1.545 | 0.00 | 0.00 | 2703 |
| 2026-11-03 | ADCT | 1.555 | 0.00 | 0.00 | 2707 |
| 2026-11-04 | ADCT | 1.72 | 0.00 | 0.00 | 2425 |
| 2026-11-05 | ADCT | 1.64 | 0.00 | 0.00 | 2425 |
| 2026-11-06 | ADCT | 1.585 | 0.00 | 0.00 | 2425 |
| 2026-11-09 | ADCT | 1.655 | 0.00 | 0.00 | 2476 |
| 2026-11-10 | ADCT | 1.505 | 0.00 | 0.00 | 2476 |
| 2026-11-11 | ADCT | 1.595 | 0.00 | 0.00 | 2515 |
| 2026-11-12 | ADCT | 1.39 | 0.00 | 0.00 | 2515 |
| 2026-11-13 | ADCT | 1.345 | 0.00 | 0.00 | 2571 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-15 | ADCT | 1.49 | - | - | -0.75 |
| 2026-10-16 | ADCT | 1.40 | - | - | -0.75 |
| 2026-10-19 | ADCT | 1.44 | - | - | -0.75 |
| 2026-10-20 | ADCT | 1.44 | - | - | -0.75 |
| 2026-10-21 | ADCT | 1.53 | - | - | -0.75 |
| 2026-10-22 | ADCT | 1.59 | - | - | -0.75 |
| 2026-10-23 | ADCT | 1.45 | - | - | -0.75 |
| 2026-10-26 | ADCT | 1.50 | - | - | -0.75 |
| 2026-10-27 | ADCT | 1.59 | - | - | -0.75 |
| 2026-10-28 | ADCT | 1.62 | - | - | -0.75 |
| 2026-10-29 | ADCT | 1.50 | - | - | -0.75 |
| 2026-10-30 | ADCT | 1.53 | - | - | -0.75 |
| 2026-11-02 | ADCT | 1.55 | - | - | -0.75 |
| 2026-11-03 | ADCT | 1.55 | - | - | -0.75 |
| 2026-11-04 | ADCT | 1.72 | - | - | -0.75 |
| 2026-11-05 | ADCT | 1.64 | - | - | -0.75 |
| 2026-11-06 | ADCT | 1.58 | - | - | -0.75 |
| 2026-11-09 | ADCT | 1.65 | - | - | -0.75 |
| 2026-11-10 | ADCT | 1.50 | - | - | -0.75 |
| 2026-11-11 | ADCT | 1.60 | - | - | -0.75 |
| 2026-11-12 | ADCT | 1.40 | - | - | -0.75 |
| 2026-11-13 | ADCT | 1.34 | - | - | -0.75 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-15 | ADCT | 0.00 | -4.03 | 6.96 |
| 2026-10-16 | ADCT | 0.00 | -4.03 | 6.96 |
| 2026-10-19 | ADCT | 0.00 | -4.04 | 6.96 |
| 2026-10-20 | ADCT | 0.00 | -4.04 | 6.96 |
| 2026-10-21 | ADCT | 0.00 | -4.04 | 6.96 |
| 2026-10-22 | ADCT | 0.00 | -4.04 | 6.96 |
| 2026-10-23 | ADCT | 0.00 | -4.04 | 6.96 |
| 2026-10-26 | ADCT | 0.00 | -4.06 | 6.96 |
| 2026-10-27 | ADCT | 0.00 | -4.06 | 6.40 |
| 2026-10-28 | ADCT | 0.00 | -4.06 | 6.40 |
| 2026-10-29 | ADCT | 0.00 | -4.06 | 6.40 |
| 2026-10-30 | ADCT | 0.00 | -4.06 | 6.40 |
| 2026-11-02 | ADCT | 0.00 | -4.14 | 6.40 |
| 2026-11-03 | ADCT | 0.00 | -4.14 | 6.40 |
| 2026-11-05 | ADCT | 0.00 | -4.14 | 6.40 |
| 2026-11-06 | ADCT | 0.00 | -4.14 | 6.40 |
| 2026-11-09 | ADCT | 0.00 | -0.85 | 6.40 |
| 2026-11-10 | ADCT | 0.00 | -0.85 | 6.40 |
| 2026-11-11 | ADCT | 0.00 | -0.85 | 6.49 |
| 2026-11-12 | ADCT | 0.00 | -0.85 | 6.49 |
| 2026-11-13 | ADCT | 0.00 | -0.85 | 6.49 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.16
Avg. EPS Est. Current Quarter
-0.2
Avg. EPS Est. Next Quarter
-0.18
Insider Transactions
Institutional Transactions
-0.85
Beta
1.8
Average Sales Estimate Current Quarter
21
Average Sales Estimate Next Quarter
20
Fair Value
Quality Score
28
Growth Score
38
Sentiment Score
3
Actual DrawDown %
95
Max Drawdown 5-Year %
-98.2
Target Price
2.62
P/E
Forward P/E
PEG
P/S
2.02
P/B
P/Free Cash Flow
EPS
-0.53
Average EPS Est. Cur. Y
-0.75
EPS Next Y. (Est.)
-0.68
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-95.73
Relative Volume
0.64
Return on Equity vs Sector %
6.2
Return on Equity vs Industry %
25.9
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
◆
ADCT
Healthcare
$1.34
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
43.4
Range 1M
11.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
37.7%
EPS NY
7.9%
52W%
13.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+95.5% upside
Upside
+95.5%
Quality
28
ADCT — P/E HistoricalBiotechnology
ADC Therapeutics SASector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 188
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
ADCT
Latest News
—
Caricamento notizie per ADCT…
stock quote shares ADCT – Adc Therapeutics SA Stock Price stock today
news today ADCT – Adc Therapeutics SA stock forecast ,stock prediction 2023 2024 2025
marketwatch ADCT – Adc Therapeutics SA yahoo finance google finance
stock history ADCT – Adc Therapeutics SA invest stock market
stock prices ADCT premarket after hours
ticker ADCT fair value insiders trading